Low-Dose 0.01% Atropine Eye Drops vs Placebo for Myopia Control: A Randomized Clinical Trial

Controlling myopia progression is of interest worldwide. Low-dose atropine eye drops have slowed progression in children in East Asia. To compare atropine, 0.01%, eye drops with placebo for slowing myopia progression in US children. This was a randomized placebo-controlled, double-masked, clinical t...

Full description

Saved in:

Bibliographic Details
Published in:	JAMA ophthalmology Vol. 141; no. 8; p. 756
Main Authors:	Repka, Michael X, Weise, Katherine K, Chandler, Danielle L, Wu, Rui, Melia, B Michele, Manny, Ruth E, Kehler, Lori Ann F, Jordan, Catherine O, Raghuram, Aparna, Summers, Allison I, Lee, Katherine A, Petersen, David B, Erzurum, S A, Pang, Yi, Lenhart, Phoebe D, Ticho, Benjamin H, Beck, Roy W, Kraker, Raymond T, Holmes, Jonathan M, Cotter, Susan A
Format:	Journal Article
Language:	English
Published:	United States 01-08-2023
Subjects:	Atropine - administration & dosage Child Child, Preschool Disease Progression Female Humans Myopia - diagnosis Myopia - drug therapy Ophthalmic Solutions - administration & dosage Refraction, Ocular Vision Tests
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Controlling myopia progression is of interest worldwide. Low-dose atropine eye drops have slowed progression in children in East Asia. To compare atropine, 0.01%, eye drops with placebo for slowing myopia progression in US children. This was a randomized placebo-controlled, double-masked, clinical trial conducted from June 2018 to September 2022. Children aged 5 to 12 years were recruited from 12 community- and institution-based practices in the US. Participating children had low to moderate bilateral myopia (-1.00 diopters [D] to -6.00 D spherical equivalent refractive error [SER]). Eligible children were randomly assigned 2:1 to 1 eye drop of atropine, 0.01%, nightly or 1 drop of placebo. Treatment was for 24 months followed by 6 months of observation. Automated cycloplegic refraction was performed by masked examiners. The primary outcome was change in SER (mean of both eyes) from baseline to 24 months (receiving treatment); other outcomes included change in SER from baseline to 30 months (not receiving treatment) and change in axial length at both time points. Differences were calculated as atropine minus placebo. A total of 187 children (mean [SD] age, 10.1 [1.8] years; age range, 5.1-12.9 years; 101 female [54%]; 34 Black [18%], 20 East Asian [11%], 30 Hispanic or Latino [16%], 11 multiracial [6%], 6 West/South Asian [3%], 86 White [46%]) were included in the study. A total of 125 children (67%) received atropine, 0.01%, and 62 children (33%) received placebo. Follow-up was completed at 24 months by 119 of 125 children (95%) in the atropine group and 58 of 62 children (94%) in the placebo group. At 30 months, follow-up was completed by 118 of 125 children (94%) in the atropine group and 57 of 62 children (92%) in the placebo group. At the 24-month primary outcome visit, the adjusted mean (95% CI) change in SER from baseline was -0.82 (-0.96 to -0.68) D and -0.80 (-0.98 to -0.62) D in the atropine and placebo groups, respectively (adjusted difference = -0.02 D; 95% CI, -0.19 to +0.15 D; P = .83). At 30 months (6 months not receiving treatment), the adjusted difference in mean SER change from baseline was -0.04 D (95% CI, -0.25 to +0.17 D). Adjusted mean (95% CI) changes in axial length from baseline to 24 months were 0.44 (0.39-0.50) mm and 0.45 (0.37-0.52) mm in the atropine and placebo groups, respectively (adjusted difference = -0.002 mm; 95% CI, -0.106 to 0.102 mm). Adjusted difference in mean axial elongation from baseline to 30 months was +0.009 mm (95% CI, -0.115 to 0.134 mm). In this randomized clinical trial of school-aged children in the US with low to moderate myopia, atropine, 0.01%, eye drops administered nightly when compared with placebo did not slow myopia progression or axial elongation. These results do not support use of atropine, 0.01%, eye drops to slow myopia progression or axial elongation in US children. ClinicalTrials.gov Identifier: NCT03334253.
ISSN:	2168-6173
DOI:	10.1001/jamaophthalmol.2023.2855